Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
To assess the effect of Empagliflozin on cardiac biomarkers, cardiac function at rest and during stress, cardiac hemodynamics, renal function, metabolism, daily activity level and health-related quality of life in stable, symptomatic heart failure patients with reduced left ventricular ejection fraction. The primary hypothesis is that 3 months\' treatment with Empagliflozin 10 mg a day will reduce the plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP).
Epistemonikos ID: 8a12a7811524dc573df30f55e39fa9b1488854ae
First added on: May 20, 2024